ArticleFrontiers in cardiovascular medicine2025
Long-term outcome of catheter ablation in patients with persistent atrial fibrillation and functional tricuspid regurgitation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Right-heart reverse remodeling and heart failure symptom outcomes after catheter ablation in patients with persistent atrial fibrillation, heart failure, and functional tricuspid regurgitation.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) and tricuspid regurgitation (TR) frequently coexist and mutually worsen each other. However, the long-term effects of functional tricuspid regurgitation (FTR) on AF recurrence and the improvement of TR after radiofrequency catheter ablation (RFCA) remain unclear. Methods: This retrospective, single-center observational study involved 1,690 patients with persistent atrial fibrillation (PsAF) who underwent AF ablation between January 2012 and June 2022. 153 paients with significant FTR were propensity matching 153 patients with no or mild FTR based on age, body mass index, and mitral regurgitation (MR) severity. Patients were followed up for at least 1 year. Procedural success was defined as freedom from any atrial tachyarrhythmia (>30 s) after the 3-month blanking period, off antiarrhythmic drugs. Significant FTR was defined as moderate to severe TR. Significant TR improvement was defined as a reduction in TR severity by ≥2 grades from pre- to post-ablation. Results: Among the observational cohort, 153 patients (9.1%) had significant FTR, the severity of which correlated with female sex, AF duration, atrial/ventricular remodeling, and NT-proBNP levels. During the 12-month follow-up, the procedural success rate was 67.6% (207/306). RFCA significantly reduced the proportion of RA and RV enlargement ( Conclusions: Significant FTR was an independent predictor of AF recurrence in patients with PsAF undergoing RFCA. The long-term success was poor in the subgroups of significant FTR and those with ventricular FTR. Furthermore, successful RFCA was associated with significantly improved FTR in patients with PsAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.